CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies. However, its limitations remain evident. In ...
CAR-T cell therapy works well in blood cancers, but many patients still become resistant. A key reason is the presence of CAR ...
Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...
CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies. However, its limitations remain evident. In ...
At AACR, first‑in‑human KIR‑CAR T data show early activity in solid tumors and introduce a novel design aimed at limiting T cell exhaustion.
Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...
Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...
CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...
Curocell, an immuno-oncology cell therapy developer, has secured approval for RIMQARTO® Inj., South Korea’s first domestically developed CAR-T therapy ...
Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results